Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression

BACKGROUND: Immunotherapy targeting programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) has been shown to be effective in a variety of malignancies but has poor efficacy in pancreatic ductal adenocarcinoma (PDAC). Studies have shown that PD-L1 expression in tumors is an important indicato...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Nan-Nan, Zhou, Min, Sun, Fang, Huai, Man-Xiu, Zhang, Yi, Qu, Chun-Ying, Shen, Feng, Xu, Lei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383845/
https://www.ncbi.nlm.nih.gov/pubmed/32774054
http://dx.doi.org/10.3748/wjg.v26.i26.3737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383845/
https://www.ncbi.nlm.nih.gov/pubmed/32774054
http://dx.doi.org/10.3748/wjg.v26.i26.3737

Ejemplares similares